注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
创胜集团医药有限公司是一家从事临床阶段生物制药的发现、研究、开发、制造和业务拓展的中国投资控股公司。该公司的产品包括MSB2311,TST001,TST005,TST002,TST004,TST003,TST008,MSB0254和TST006。该公司产品均处于研发阶段,尚未市场化。该公司还提供合同开发和生产(CDMO)服务,主要包括工艺开发服务、GMP/cGMP生产服务、细胞株开发服务、样品检测服务、配方优化服务及成药性研究。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Xueming Qian | 53 | 2012 | CEO & Executive Director |
Yining Zhao | 50 | 2018 | Non-Executive Chairman |
Briggs W. Morrison | 64 | - | Chairman of Scientific Advisory Board |
Kumar Srinivasan | 59 | 2022 | Independent Non-Executive Director |
Pasi Antero Janne | - | - | Member of Scientific Advisory Board |
Ling Su | 59 | - | Member of Scientific Advisory Board |
Zhihua Zhang | 41 | 2021 | Independent Non-Executive Director |
Susan M. Jerian | - | - | Member of Scientific Advisory Board |
Wei Chen | 56 | 2023 | Independent Non-Executive Director |
Jiasong Tang | 50 | 2021 | Independent Non-Executive Director |
Li Xu | - | 2021 | Member of Scientific Advisory Board & Strategic Advisor to CEO |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核